STAT News

STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…

By STAT News

1 min read
STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights